An early-stage biotech company, Empiri is currently focused on addressing/achieving precision oncology - structured around revolutionizing the way cancer is treated. The focus is on providing before treatments, empirical, personalized drug response data selected for each patient by oncologists. Principals of the firm are building LDTs for specific cancer indications and a first-in-class automated cancer diagnostic instrument to scale the company's assays. The firm is also a 10x Genomic Certified Service Provider for single-cell analysis for clinical and preclinical studies.
